BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics


BioXcel Therapeutics, Inc. (BTAI): $37.11

-0.40 (-1.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BTAI Stock Price Chart Interactive Chart >

Price chart for BTAI

BTAI Price/Volume Stats

Current price $37.11 52-week high $71.50
Prev. close $37.51 52-week low $28.00
Day low $36.56 Volume 104,710
Day high $37.46 Avg. volume 460,701
50-day MA $34.11 Dividend yield N/A
200-day MA $44.79 Market Cap 914.09M

BioXcel Therapeutics, Inc. (BTAI) Company Bio


BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.


BTAI Latest News Stream


Event/Time News Detail
Loading, please wait...

BTAI Latest Social Stream


Loading social stream, please wait...

View Full BTAI Social Stream

Latest BTAI News From Around the Web

Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.

Analyst Ratings for BioXcel Therapeutics

Within the last quarter, BioXcel Therapeutics (NASDAQ: BTAI ) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 1 3 Somewhat Bullish 0 0 0 0 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for BioXcel Therapeutics. The company has an average price target of $136.33 with a high of $176.00 and a low of $75.00. This current average represents a 13.72% increase from the previous average price target of $158.0. What Are Analyst Ratings? Ratings come Full story available on Benzinga.com

Benzinga | June 1, 2021

BioXcel: Upcoming PDUFA Makes Recent Drop Attractive

Photo by Design Cells/iStock via Getty ImagesI covered BioXcel Therapeutics (BTAI) last year when it was yet to submit an NDA for its lead program. This was for sublingual formulation of dexmedetomidine ((DEX)), a selective alpha-2 adrenergic receptor agonist, targeting acute agitation in schizophrenia/bipolar patients. The molecule obtained primary endpoints...

Avisol Capital Partners on Seeking Alpha | May 29, 2021

BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel, will participate in fireside chats at three upcoming virtual healthcare investor conferences.

BioSpace | May 25, 2021

BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

FDA sets PDUFA action date for January 5, 2022 If approved, BXCL501 would represent the first major advancement in the acute treatment of agitation associated with schizophrenia and bipolar disorders in almost a decade

BioSpace | May 18, 2021

BioXcel Therapeutics (NASDAQ:BTAI) Given New $170.00 Price Target at HC Wainwright

BioXcel Therapeutics (NASDAQ:BTAI) had its target price reduced by HC Wainwright from $175.00 to $170.00 in a research report report published on Tuesday morning, PriceTargets.com reports. HC Wainwright currently has a buy rating on the stock. A number of other brokerages have also recently weighed in on BTAI. Canaccord Genuity cut their price objective on []

Dakota Financial News | May 12, 2021

Read More 'BTAI' Stories Here

BTAI Price Returns

1-mo 17.85%
3-mo -17.09%
6-mo -27.60%
1-year -32.34%
3-year 327.53%
5-year N/A
YTD -19.68%
2020 216.22%
2019 278.50%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8891 seconds.